1-3 of 3
Tadashi Matsushita
Close
Sort by
Journal Articles

The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A

Clinical Trials & Observations
Christoph Male, Christoph Königs, Sohan Dey, Tadashi Matsushita, Anders Holm Millner, Marek Zak, Guy Young, Gili Kenet
Journal: Blood Advances
Blood Adv (2023) 7 (4): 620–629.
https://doi.org/10.1182/bloodadvances.2022007529
Published: 2023
Includes: Supplemental data
Journal Articles

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors

Clinical Trials & Observations
Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Hermann Eichler, Victor Jiménez-Yuste, Kaan Kavakli, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P. Wheeler, Guy Young, Silva Zupančić-Šalek, Johannes Oldenburg, Pratima Chowdary
Journal: Blood Advances
Blood Adv (2022) 6 (11): 3422–3432.
https://doi.org/10.1182/bloodadvances.2021006403
Published: 2022
Includes: Supplemental data
Journal Articles

Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors

Clinical Trials & Observations
Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato, Katsuyuki Fukutake, Ryu Kasai, Koichiro Yoneyama, Hiroki Yoshida, Keiji Nogami
Journal: Blood Advances
Blood Adv (2017) 1 (22): 1891–1899.
https://doi.org/10.1182/bloodadvances.2017006684
Published: 2017
Includes: Supplemental data